The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.
Status:
Completed
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Using eltronmobag as an alternative pathway, which depend on stimulation of thrombocyte
synthesis, in chronic and persistent immune thrombocytopenia may be more promising treatment
than the classic type, not only by increasing platelets count but also through enhancing of
the platelets activation and upregulation of GPVI expression on platelet surface.
This study will include 40 pediatric patients with chronic or persistent ITP, recruited from
the Hematology clinic of pediatric hospital Ain Shams University, aiming to investigate the
efficacy, & the safety and tolerability of eltrombopag therapy for children as well as the
ability of eltrombopag to enhance the platelet activation through the up-regulation of
glycoprotein VI (GPVI) receptor expression in comparison with other lines of treatment.
Patients will be divided into 2 groups : Group 1 on eltrombopag ; Group 2 : receiving other
lines of therapy .
All Patients will be subjected to :
1. bleeding score assessment ( baseline &every month ) and Health related quality of life
based on Kids' ITP Tools (KIT) questionnaires( baseline and week 24 )
2. Baseline and at week 24 bone marrow examination with reticulin stain
3. clinical examination every 2 weeks and complete blood counts.
4. Assessment of soluble form of glycoprotein VI using sandwich enzyme-linked immunosorbent
assay (ELISA) as well as assessment of platelet activation by GPVI using flowcytometry
(Gardiner, etal.,2010 ) at baseline and at the end of 6 months treatment period